Pharmacogenetics in Rheumatoid Arthritis
- 3 July 2014
- book chapter
- Published by Springer Nature
- Vol. 1175, 625-660
Abstract
Rheumatoid arthritis (RA) is a systemic inflammatory arthritis leading to severe joint damage and associated with high morbidity and mortality. Disease-modifying antirheumatic drugs (DMARDs) are the mainstay of treatment in RA. DMARDs not only relieve the clinical signs and symptoms of RA but also inhibit the radiographic progression of disease. In the last decade, a new class of disease-modifying medications, the biologic agents, has been added to the existing spectrum of DMARDs in RA. However, patients’ response to these agents is not uniform with considerable variability in both efficacy and toxicity. There are no reliable means of predicting an individual patient’s response to a given DMARD prior to initiation of therapy. In this chapter, the current published literature on the pharmacogenetics of traditional DMARDS and the newer biologic DMARDs in RA is highlighted. Pharmacogenetics may help individualize drug therapy in patients with RA in the near future.Keywords
This publication has 129 references indexed in Scilit:
- Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2013
- Influence ofFCGR3Agenotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort studyBMJ Open, 2012
- Replication of association of the PTPRC gene with response to anti–tumor necrosis factor therapy in a large UK cohortArthritis & Rheumatism, 2011
- Genome‐wide association study of genetic predictors of anti–tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven lociArthritis & Rheumatism, 2010
- Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatmentAnnals of the Rheumatic Diseases, 2010
- Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genesHuman Molecular Genetics, 2009
- Rheumatoid arthritis: a view of the current genetic landscapeGenes & Immunity, 2008
- CD226 Gly307Ser association with multiple autoimmune diseasesGenes & Immunity, 2008
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritisArthritis & Rheumatism, 1987